Lyell Immunopharma Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 161

Employees

  • Stock Symbol
  • LYEL

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $14.62
  • (As of Monday Closing)

Lyell Immunopharma General Information

Description

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Contact Information

Website
www.lyell.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 201 Haskins Way
  • Suite 101
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 201 Haskins Way
  • Suite 101
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lyell Immunopharma Stock Performance

As of 16-Nov-2026, Lyell Immunopharma’s stock price is $14.62. Its current market cap is $468M with 32M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$14.62 $14.30 $7.20 - $45.00 $468M 32M 178K -$12.61

Lyell Immunopharma Financials Summary

As of 30-Sep-2026, Lyell Immunopharma has a trailing 12-month revenue of $15K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 72,737 378,550 (202,123) (28,229)
Revenue 15 36 61 130
EBITDA (255,114) (275,989) (347,431) (237,835)
Net Income (255,160) (274,448) (342,994) (234,632)
Total Assets 273,854 340,052 490,859 750,029
Total Debt 34,315 50,994 58,968 63,167
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lyell Immunopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lyell Immunopharma‘s full profile, request access.

Request a free trial

Lyell Immunopharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Lyell Immunopharma‘s full profile, request access.

Request a free trial

Lyell Immunopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation
Drug Discovery
South San Francisco, CA
161 As of 2025

Boston, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lyell Immunopharma Competitors (48)

One of Lyell Immunopharma’s 48 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Boston, MA
ORIC Pharmaceuticals Formerly VC-backed South San Francisco, CA
Kyverna Formerly VC-backed Emeryville, CA
Instil Bio Formerly VC-backed Dallas, TX
Aclaris Therapeutics Formerly VC-backed Wayne, PA
You’re viewing 5 of 48 competitors. Get the full list »

Lyell Immunopharma Patents

Lyell Immunopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026102456-A1 Methods of treating cancer by administering bispecific cd19/cd20 car t cells Pending 11-Nov-2024
WO-2026006604-A1 Feeder cell replacement Pending 26-Jun-2024
WO-2025217398-A1 Methods for culturing cells with improved culture medium Pending 10-Apr-2024
WO-2025096419-A1 T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof Inactive 31-Oct-2023
WO-2025058919-A1 Bispecific chimeric antigen receptors and use thereof Inactive 12-Sep-2023 C07K16/28
To view Lyell Immunopharma’s complete patent history, request access »

Lyell Immunopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lyell Immunopharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lyell Immunopharma‘s full profile, request access.

Request a free trial

Lyell Immunopharma Investments & Acquisitions (8)

Lyell Immunopharma’s most recent deal was a Corporate Asset Purchase with Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) for . The deal was made on 10-Nov-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Innovative Cellular Therapeutics (Global Rights of CAR T-Cell Candidate for Colorectal Cancer) 10-Nov-2025 Corporate Asset Purchase Buildings and Property
ImmPACT Bio 31-Oct-2024 Merger/Acquisition Drug Discovery
Outpace Bio 03-Feb-2021 Early Stage VC Discovery Tools (Healthcare)
Sonoma Biotherapeutics 30-Sep-2020 Early Stage VC Drug Discovery
Immulus 23-May-2020 Early Stage VC Biotechnology
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Lyell Immunopharma ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

33.64 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Lyell Immunopharma’s complete esg history, request access »

Lyell Immunopharma Exits (3)

Lyell Immunopharma’s most recent exit was on 23-May-2020 from Immulus. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Immulus 23-May-2020 Completed
  • 2 buyers
PACT Pharma 10-Jan-2020 Completed
  • 17 buyers
CERo Therapeutics Holdings 26-Nov-2019 Early Stage VC Completed
  • 5 buyers
To view Lyell Immunopharma’s complete exits history, request access »

Lyell Immunopharma FAQs

  • When was Lyell Immunopharma founded?

    Lyell Immunopharma was founded in 2018.

  • Where is Lyell Immunopharma headquartered?

    Lyell Immunopharma is headquartered in South San Francisco, CA.

  • What is the size of Lyell Immunopharma?

    Lyell Immunopharma has 161 total employees.

  • What industry is Lyell Immunopharma in?

    Lyell Immunopharma’s primary industry is Drug Discovery.

  • Is Lyell Immunopharma a private or public company?

    Lyell Immunopharma is a Public company.

  • What is Lyell Immunopharma’s stock symbol?

    The ticker symbol for Lyell Immunopharma is LYEL.

  • What is the current stock price of Lyell Immunopharma?

    As of 16-Nov-2026 the stock price of Lyell Immunopharma is $14.62.

  • What is the current market cap of Lyell Immunopharma?

    The current market capitalization of Lyell Immunopharma is $468M.

  • What is Lyell Immunopharma’s current revenue?

    The trailing twelve month revenue for Lyell Immunopharma is $15K.

  • Who are Lyell Immunopharma’s competitors?

    Aura Biosciences, ORIC Pharmaceuticals, Kyverna, Instil Bio, and Aclaris Therapeutics are some of the 48 competitors of Lyell Immunopharma.

  • What is Lyell Immunopharma’s annual earnings per share (EPS)?

    Lyell Immunopharma’s EPS for 12 months was -$12.61.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process